May 6, 2019
The medical center earned The Joint Commission’s Gold Seal of Approval® for Center of Excellence for Pancreas, Liver, and Bile Duct Cancer Certification – the first medical center in New Jersey to receive this accreditation
Hackensack Meridian Health Cancer Care today announced that Jersey Shore University Medical Center has earned The Joint Commission’s Gold Seal of Approval® for Center of Excellence for Pancreas, Liver, and Bile Duct Cancer Certification. The Gold Seal of Approval® is a symbol of quality that reflects an organization’s commitment to providing safe and effective patient care. The medical center is the first in New Jersey to receive this accreditation.
“Jersey Shore University Medical Center is pleased to receive this Disease-Specific Care Certification from The Joint Commission, the premier health care quality improvement and accrediting body in the nation,” noted Ronald Matteotti, M.D., medical director of the Hepatobiliary & Pancreatic Program and Chief of Hepatobiliary & Pancreatic Surgery at Jersey Shore University Medical Center. “This certification provides us with the framework to create a culture of excellence for those in our community. It is a huge accomplishment in recognition of our high-quality program and shows that patients with hepatobiliary cancers can receive the most advanced care right here in Monmouth and Ocean Counties, without the need to leave the area.”
Ronald Matteotti, M.D., FMH, FACS, ABIHM, DABS, is an internationally acclaimed double board certified surgeon who leads this challenging disease site with his team. He was instrumental in building the hepatobiliary program over the last five years.
“Our goal is to provide every patient an individualized treatment plan following NCCN guidelines, and to have a first treatment/workup decision within 24-48 hours from when the patient contacts our team. We have the capability and resources for a fast turn-around with streamlined processes and direct communication between our team and necessary specialists.”
Jersey Shore University Medical Center underwent a rigorous on-site review in February. Joint Commission experts evaluated compliance with national disease-specific care standards as well as with hepatobiliary cancer-specific requirements. Clinical practice guidelines and performance measures also were assessed.
To learn more about the Hepatobiliary / Pancreas program, please visit us online at www.hackensackmeridianhealth.org/services/cancer-care/cancer-services/hepatobiliary-and-pancreatic or call 732-776-4770.
Established in 2002 and awarded for a two-year period, The Joint Commission’s Disease-Specific Care Certification evaluates clinical programs across the continuum of care and addresses three core areas:
- Compliance with consensus-based national standards;
- Effective use of evidence-based clinical practice guidelines to manage and optimize care;
- An organized approach to performance measurement and improvement activities.
“Jersey Shore University Medical Center has thoroughly demonstrated a high level of care for patients with cancers of the pancreas, liver, and bile ducts,” said Patrick Phelan, executive director, Hospital Business Development, The Joint Commission. “We commend Hackensack Meridian Health Cancer Care for becoming a leader in hepatobiliary cancer care, potentially providing a higher standard of service for patients in its community with these challenging cancers.”
Cancers of the pancreas, liver, and bile ducts are highly complex and often advanced by the time they are diagnosed. They require a multidisciplinary team approach and advanced technologies to give patients the best chance of a good outcome.
At Hackensack Meridian Health Cancer Care in Monmouth and Ocean Counties, patients have access to comprehensive, compassionate care including world-class surgical, medical and radiation oncology expertise with access to clinical trials. We offer a multidisciplinary approach to care for all types of cancers and supportive programs and resources from diagnosis through treatment and after care.